JP2021520393A5 - - Google Patents

Info

Publication number
JP2021520393A5
JP2021520393A5 JP2020554864A JP2020554864A JP2021520393A5 JP 2021520393 A5 JP2021520393 A5 JP 2021520393A5 JP 2020554864 A JP2020554864 A JP 2020554864A JP 2020554864 A JP2020554864 A JP 2020554864A JP 2021520393 A5 JP2021520393 A5 JP 2021520393A5
Authority
JP
Japan
Prior art keywords
antibody
fragment
seq
amino acid
antigen
Prior art date
Application number
JP2020554864A
Other languages
English (en)
Japanese (ja)
Other versions
JP7437317B2 (ja
JPWO2019195273A5 (https=
JP2021520393A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/025363 external-priority patent/WO2019195273A1/en
Publication of JP2021520393A publication Critical patent/JP2021520393A/ja
Publication of JPWO2019195273A5 publication Critical patent/JPWO2019195273A5/ja
Publication of JP2021520393A5 publication Critical patent/JP2021520393A5/ja
Priority to JP2024018521A priority Critical patent/JP7829605B2/ja
Application granted granted Critical
Publication of JP7437317B2 publication Critical patent/JP7437317B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020554864A 2018-04-02 2019-04-02 コネキシン４３抗体およびその使用 Active JP7437317B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024018521A JP7829605B2 (ja) 2018-04-02 2024-02-09 コネキシン４３抗体およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862651668P 2018-04-02 2018-04-02
US62/651,668 2018-04-02
PCT/US2019/025363 WO2019195273A1 (en) 2018-04-02 2019-04-02 Connexin 43 antibodies and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024018521A Division JP7829605B2 (ja) 2018-04-02 2024-02-09 コネキシン４３抗体およびその使用

Publications (4)

Publication Number Publication Date
JP2021520393A JP2021520393A (ja) 2021-08-19
JPWO2019195273A5 JPWO2019195273A5 (https=) 2022-04-11
JP2021520393A5 true JP2021520393A5 (https=) 2022-04-11
JP7437317B2 JP7437317B2 (ja) 2024-02-22

Family

ID=68101187

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020554864A Active JP7437317B2 (ja) 2018-04-02 2019-04-02 コネキシン４３抗体およびその使用
JP2024018521A Active JP7829605B2 (ja) 2018-04-02 2024-02-09 コネキシン４３抗体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024018521A Active JP7829605B2 (ja) 2018-04-02 2024-02-09 コネキシン４３抗体およびその使用

Country Status (6)

Country Link
US (2) US12227561B2 (https=)
JP (2) JP7437317B2 (https=)
CN (2) CN116854816A (https=)
AU (1) AU2019249427B2 (https=)
CA (1) CA3095897A1 (https=)
WO (1) WO2019195273A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3095897A1 (en) 2018-04-02 2019-10-10 Alamab Therapeutics, Inc. Connexin 43 antibodies and use thereof
AU2020219112A1 (en) * 2019-02-04 2021-08-26 Alamab Therapeutics, Inc. Connexin 43 antibodies and use thereof
US20220162298A1 (en) * 2019-02-28 2022-05-26 Board Of Regents, The University Of Texas System Compositions for treating osteosarcoma and methods of use
KR20220113355A (ko) * 2019-10-02 2022-08-12 알라맵 테라퓨틱스, 인크. 항-코넥신 항체 제제
CN113307871B (zh) * 2020-02-27 2023-05-02 福州拓新天成生物科技有限公司 新型抗cd19抗体和cd19-car-t细胞的制备及其应用
WO2022026914A1 (en) * 2020-07-31 2022-02-03 Alamab Therapeutics, Inc. Anti-connexin antibody formulations
EP4720129A2 (en) * 2023-05-24 2026-04-08 Alamab Therapeutics, Inc. Method of treating bone cancers
US12571255B2 (en) 2023-06-02 2026-03-10 Universal Electronics Inc. Systems and method for controlling window treatments

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
JP4063769B2 (ja) 2001-12-28 2008-03-19 中外製薬株式会社 タンパク質安定化方法
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
NZ547157A (en) 2003-12-10 2009-07-31 Medarex Inc Interferon Alpha Antibodies and their uses
KR102073629B1 (ko) 2005-02-03 2020-02-05 코다 테라퓨틱스 (엔지) 리미티드 항-코넥신 화합물 및 그의 용도
MX2010012324A (es) * 2008-05-15 2011-01-14 Biogen Idec Inc Anticuerpos anti-fn14 y usos de los mismos.
US20110223204A1 (en) 2008-06-04 2011-09-15 Bradford J Duft Treatment of pain with gap junction modulation compounds
CA2823154A1 (en) 2010-12-27 2012-07-05 Lsip, Llc Ips cells and method for generating same
CN114621346B (zh) * 2013-08-21 2025-06-10 德克萨斯州大学系统董事会 用于靶向连接蛋白半通道的组合物和方法
US9493552B2 (en) * 2013-11-15 2016-11-15 China Synthetic Rubber Corporation Therapeutic biologic for treatment of hepatocellular carcinoma
CN107109410B (zh) 2014-08-22 2021-11-02 奥克兰联合服务有限公司 通道调节剂
WO2017024465A1 (en) * 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
WO2017147561A1 (en) * 2016-02-26 2017-08-31 The Board Of Regents Of The University Of Texas System CONNEXIN (Cx) 43 HEMICHANNEL-BINDING ANTIBODIES AND USES THEREOF
CA3095897A1 (en) 2018-04-02 2019-10-10 Alamab Therapeutics, Inc. Connexin 43 antibodies and use thereof
AU2020219112A1 (en) 2019-02-04 2021-08-26 Alamab Therapeutics, Inc. Connexin 43 antibodies and use thereof
WO2022026914A1 (en) * 2020-07-31 2022-02-03 Alamab Therapeutics, Inc. Anti-connexin antibody formulations

Similar Documents

Publication Publication Date Title
JP2021520393A5 (https=)
JP2020537644A5 (https=)
RU2376316C2 (ru) Человеческие антитела против человеческого 4-1вв (cd137)
JP2020062036A5 (https=)
JP2020519643A5 (https=)
JP2017529838A5 (https=)
JP2017500018A5 (https=)
JP2020502271A5 (https=)
JP2019527194A5 (https=)
JP2019535763A5 (https=)
JP2022513420A5 (https=)
JP2011509245A5 (https=)
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
JP2017532952A5 (https=)
JP2008542278A5 (https=)
JP2014502955A5 (https=)
JP2014076062A5 (https=)
JP2017113019A5 (https=)
JP2010526028A5 (https=)
JP2015509948A5 (https=)
JP2015523962A5 (https=)
JP2013537418A5 (https=)
JP2019522961A5 (https=)
JPWO2020059847A5 (https=)
JP2015503909A5 (https=)